Overview
To access this data, please log into DSS and submit an application.
Within the application, add this dataset (accession NG00147) in the “Choose a Dataset” section.
Once approved, you will be able to log in and access the data within the DARM portal.
Description
The ANGI GWAS dataset includes demographics, APOE genotype, and GWAS data for participants from the ANGI cohort. This dataset also includes amyloid PET scan results (positive, negative, uninterpretable, not yet reported), level of cognitive impairment (no impairment, MCI, Dementia), year of onset of cognitive impairment, most etiological causes of impairment (pre and post scan), year enrolled in IDEAS, year of amyloid PET scan, year of post-PET visit, MMSE score, and type of MCI (if applicable, amnestic or non-amnestic). Request additional ANGI data including IDEAS imaging and clinical data through the IDEAS website.
Sample Summary per Data Type
Sample Set | Accession | Data Type | Number of Samples |
---|---|---|---|
ANGI GWAS | snd10081 | Genotyping SNP Array | 1,647 |
Available Filesets
Name | Accession | Latest Release | Description |
---|---|---|---|
ANGI: GWAS, Phenotype files | fsa000102 | NG00147.v1 | GWAS, Phenotypes |
View the File Manifest for a full list of files released in this dataset.
Sample information
The first release includes quality controlled GWAS data on 1,647 participants from the ANGI cohort. It also includes phenotypes provided by the ANGI Study.
Sample Set | Accession Number | Number of Subjects | Number of Samples |
---|---|---|---|
ANGI GWAS | snd10081 | 1,647 | 1,647 |
Related Studies
- The Amyloid Neuroimaging and Genetics Initiative (ANGI) is an add-on study for people who had participated in the IDEAS (Imaging Dementia—Evidence For Amyloid Scanning) Study. The IDEAS-Study is nationwide research…
Consent Levels
Consent Level | Number of Subjects |
---|---|
GRU-IRB-PUB | 1,647 |
Visit the Data Use Limitations page for definitions of the consent levels above.
Acknowledgement
Acknowledgment statement for any data distributed by NIAGADS:
Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer’s Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.
Use the study-specific acknowledgement statements below (as applicable):
For investigators using any data from this dataset:
Please cite/reference the use of NIAGADS data by including the accession NG00147.
For investigators using Amyloid Neuroimaging and Genetics Initiative (ANGI) (sa000049) data:
The ANGI study is supported by the Alzheimer’s Association Grant ANGI/IDEAS-17-497186. We thank the Alzheimer’s Association for their support and the ANGI study participants for their contribution to the study. We would also like to acknowledge the Imaging Dementia – Evidence for Amyloid Scanning Study (iDEAS) from whom amyloid imaging and other clinical data were obtained.
Related Publications
Rabinovici GD., Gatsonis C., et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019 Apr. doi: 10.1001/jama.2019.2000. PubMed link
Approved Users
- Investigator:Belloy, MichaelInstitution:Washington University in St LouisProject Title:Elucidating sex-specific risk for Alzheimer's disease through state-of-the-art genetics and multi-omicsDate of Approval:January 6, 2025Request status:ApprovedResearch use statements:Show statementsTechnical Research Use Statement:• Objectives: In this project, we seek to holistically investigate the genetic and molecular drivers of sex dimorphism in Alzheimer’s disease across ancestries. • Study design: This study integrates large-scale population genetics with multi-omics and endophenotype analyses. We are integrating all data available from ADGC and ADSP, together with other data from AMP-AD and biobanks such as UKB, FinnGen, and MVP to conduct large-scale multi-ancestry GWAS, rare-variant gene aggregation analyses, QTL studies, PWAS, TWAS, etc. We also particularly focus on X chromosome association studies. The study design also interrogates interactions with ancestry, hormone exposures, and with APOE*4, as well as comparisons to non-stratified GWAS/XWAS of Alzheimer’s disease. Further, we will also employ genetic correlation analyses, mendelian randomization, colocalization, and pleiotropy analyses, to interrogate overlap with other complex traits to better understand the mechanisms underlying sex dimorphism in Alzheimer’s disease. • Analysis plan, including the phenotypic characteristics that will be evaluated in association with genetic variants: Our phenotypes will include Alzheimer’s disease risk, conversion risk, various endophenotypes (including amyloid/tau biomarkers, brain imaging metrics, etc.) as well as molecular traits. As noted above, we will conduct large-scale multi-ancestry GWAS, XWAS, rare-variant gene aggregation analyses, QTL studies, PWAS, TWAS, etc. Specific aims include interrogating these question and analyses on (1) the autosomes, (2) the X chromosome, and (3) leveraging sex stratified QTL studies to drive discovery of risk genes.Non-Technical Research Use Statement:Alzheimer’s disease (AD) manifests itself differently across men and women, but the genetic and molecular factors that drive this remain elusive. AD is the most common cause of dementia and till today remains largely untreatable. It is thus crucial to study the genetics of AD in a sex-specific manner, as this will help the field gain important insights into disease pathophysiology, identify novel sex-specific risk factors relevant to personalized genetic medicine, and uncover potential new AD drug targets that may benefit both sexes. This project uses large-scale genomics and multi-omics to elucidate novel sex agnostic and sex-specific AD risk genes. We will interrogate sex dimorphism for AD risk on the autosomes and the sex chromosomes. We similarly interrogate sex dimorphism in the genetic regulation of gene expression and protein levels, which we will integrate with genetic risk for Alzheimer’s disease to further discovery risk genes. Throughout, we will also interrogate how sex-specific risk for AD interactions with hormone exposures, ancestry, and the APOE*4 risk allele.
- Investigator:Cruchaga, CarlosInstitution:Washington University School of MedicineProject Title:The Familial Alzheimer Sequencing (FASe) ProjectDate of Approval:March 18, 2025Request status:ApprovedResearch use statements:Show statementsTechnical Research Use Statement:The goal of this study is to identify new genes and mutations that cause or increase risk for Alzheimer disease (AD), as well as protective factors. Individuals and families were selected from the Knight-ADRC (Washington University) and the NIA-LOAD study. Only families with at least three first-degree affected individuals were included. Families with pathogenic variants in the known AD or FTD genes, or in which APOE4 segregated with disease were excluded. At least two cases and one control were selected per family. Cases had an age at onset (AAO) after 65 yo and controls had a larger age at last assessment than the latest AAO within the family. Whole exome (WES) and whole genome sequencing (WGS) was generated for 1,235 individuals (285 families) that together with data from our collaborators and the ADSP family-based cohort (3,449 individuals and 757 families) will provide enough statistical power to identify new genes for AD. Dr. Tanzi (Harvard Medical School) will provide WGS from 400 families from the NIMH Alzheimer disease genetics initiative study. We will perform single variant and gene-based analyses to identify genes and variants that increase risk for disease in AD families. Single variant analysis will consist of a combination of association and segregation analyses. We will run family-based gene-based methods to identify genes that show and overall enrichment of variants in AD cases. We will also look for protective and modifier variants. To do this we will identify families loaded with AD cases, that also include individuals with a high burden of known risk variants but that do not develop the disease (escapees). We will use the sequence data and the family structure to identify variants that segregate with the escapee phenotype. The most promising variants and genes will be replicated in independent datasets (ADSP case-control, ADNI, Knight-ADRC, NIA-LOAD ). We will perform single variant and gene-based analyses to replicate the initial findings, and survival analysis to replicate the protective variants. We will select the most promising variants/genes for functional studiesNon-Technical Research Use Statement:Family-based approaches led to the identification of disease-causing Alzheimer’s Disease (AD) variants in the genes encoding APP, PSEN1 and PSEN2. The identification of these genes led to the A?-cascade hypothesis and to the development of drugs that target this pathway. Recently, we have identified rare coding variants in TREM2, ABCA7, PLD3 and SORL1 with large effect sizes for risk for AD, confirming that rare coding variants play a role in the etiology of AD. In this proposal, we will identify rare risk and protective alleles using sequence data from families densely affected by AD. We hypothesize that these families are enriched for genetic risk factors. We already have sequence data from 695 families (2,462 individuals), that combined with the ADSP and the NIMH dataset will lead to a dataset of more than 1,042 families (4,684 individuals). Our preliminary results support the flexibility of this approach and strongly suggest that protective and risk variants with large effect size will be found, which will lead to a better understanding of the biology of the disease.
- Investigator:Kamboh, M. IlyasInstitution:University of PittsburghProject Title:Genetics of Alzheimer's Disease and EndophenotypesDate of Approval:January 7, 2025Request status:ApprovedResearch use statements:Show statementsTechnical Research Use Statement:Objectives: We are requesting access to the NIAGADS datasets to augment our ongoing studies on the genetics of Alzheimer’s disease (AD) and AD-related endophenotypes being carried out by Kamboh and his group since 1995. We are doing GWAS using array genotypes, whole-exome sequencing and whole-genome sequencing on datasets derived from University of Pittsburgh ADRC and ancillary population-based longitudinal studies on dementia and biomarkers. Different available phenotypes include AD and non-AD dementia, age-at-set, disease progression and survival, neuroimaging, cognitive decline, plasma biomarkers for the core ATN and non-ATN pathologies. We also plan to expand on gene-gene interaction and sex-stratified analyses which require the actual genotype data. The NIAGADS datasets will be used for replication and meta-analysis, and for gene-gene interaction and sex-stratified analyses. Study Design: A case-control design will incorporate a diverse cohort of individuals with AD and age-matched controls. For quantitative traits (neuroimaging and plasma biomarkers, cognitive performance measures, indicators of disease progression), linear regression analyses will be performed to identify genetic loci. To ensure the findings are robust and inclusive, participants from diverse demographic backgrounds will be included, enabling the exploration of potential genetic variations across populations. Analysis Plan: We will conduct GWAS and targeted analyses on candidate genes on different AD and AD-related phenotypes. Primary phenotypic variables include AD disease status, age-at-onset, last age for controls, APOE genotype, cognitive decline trajectories, sex, and race. Analyses will evaluate the influence of specific genetic variants on disease risk, cognitive performance, and biomarker levels, considering both individual and interactive effects of the APOE genotype. Results will be adjusted for potential confounders, such as demographic factors, to ensure valid associations. Detail analytical methods are described in our published papers for case-control (PMID: 32651314;35694926), quantitative traits (PMID: 30361487;37666928), and cognitive decline (PMID: 37089073; 30954325).Non-Technical Research Use Statement:Our research group at the University of Pittsburgh (Pitt), has been working on the genetics of Alzheimer’s disease (AD) and AD-related endophenotypes for almost three decades, on data derived largely from the University of Pittsburgh Alzheimer’s Disease Research Center and ancillary dementia studies. We are requesting access to the NIAGADS genotype and phenotype datasets to augment our sample size to increase power to detect novel genetic associations with AD and related endophenotypes.
- Investigator:Zhao, ZhongmingInstitution:University of Texas Health Science Center at HoustonProject Title:AIM-AI: an Actionable, Integrated and Multiscale genetic map of Alzheimer's disease via deep learningDate of Approval:March 27, 2025Request status:ApprovedResearch use statements:Show statementsTechnical Research Use Statement:Objectives: The objective of our study is to advance our understanding of the genetic basis of Alzheimer’s Disease (AD) through the analysis of comprehensive genomic datasets such as Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), single-nuclei RNA sequencing, and Genome-Wide Association Studies (GWAS), as well as the related phenotype. We aim to identify genetic variants that are integral to the development and progression of AD.Study Design: Our approach involves a detailed multi-omics analysis focusing on both coding and non-coding regions within these datasets. We will develop new analytical variables from existing data, ensuring that our research adheres to the established data use limitations and contributes meaningfully to the field of genetic research in AD.Analysis Plan: The plan centers on investigating the correlation between genetic variants and AD, exploring how these variants influence the disease at a genetic level. We will employ cutting-edge computational methods to analyze interactions between these genetic markers and their potential role in AD pathogenesis. The integration of data from multiple sources will be carefully executed to maintain compliance with data use agreements, emphasizing the scientific exploration of AD.Non-Technical Research Use Statement:Our research is dedicated to unraveling the genetic components of Alzheimer’s Disease. By analyzing genetic sequences and variations through various genomic datasets, we seek to deepen the scientific understanding of how these genetic elements contribute to AD. The outcomes of this study will be shared with the public, enhancing general knowledge of Alzheimer’s Disease and supporting the global research community in its ongoing efforts to decode this complex condition.
- Investigator:Zhou, WenyuInstitution:Teal Omics. IncProject Title:Understanding CNS diseases through organ specific aging biomarkersDate of Approval:February 27, 2025Request status:ApprovedResearch use statements:Show statementsTechnical Research Use Statement:Can blood-based protein biomarkers of aging predict functional decline in organ health and in systemic health? We have developed organ-specific aging models derived from plasma proteins, and previously found that the blood proteome can be used to monitor organ health and aging in smaller cohorts (Oh, et., al., Nature 624, 164–172 (2023)). We aim to test this hypothesis at scale with diversified datasets. Aim 1. Validate our approach to modeling aging and brain health with NIAGADS cohorts. Approach: we will use protein biomarker data from cohorts to train machine learning models of organ aging. We will employ machine learning best practice for data curation, data augmentation, data normalization, and training/testing, to evaluate whether we can reproducibly estimate brain aging in diversified healthy cohorts and disease cohorts. Aim 2. Test the effects of brain aging on future disease risk and functional decline. We will focus particularly on the aging brain to investigate the relationship between organ aging and cognitive decline. Approach: we will evaluate the relationships between our model aging predictions and aging, diseases, and clinical phenotypes, such as mortality and lab and physical assessments. This is primarily done by first calculating the difference between a sample’s chronological age and its predicted organ age. This organ age residual is then tested for association with phenotypes of interest, such as Alzheimer’s Disease status or future risk of cognitive decline.Non-Technical Research Use Statement:As we age, our risk of getting sick increases, but did you know that everyone ages differently? Some people's bodies deteriorate faster than others, and we don't fully understand why. By studying how our bodies change with age, we aim to identify which organs are aging the most and find ways to improve quality of life tailored to each individual's needs. We want to understand how people age differently, both as individuals and as a population on organ specific levels. By analyzing molecules in blood, we aim to: - Identify how aging affects people uniquely - Link aging patterns to diseases and lifespan - Use advanced computer models to connect blood changes to organ function Our research can lead to: - Personalized patient care - New discoveries for medicines - Improved understanding of aging and age-related diseases We'll use a large, diverse dataset to validate our approach and gain valuable insights into the aging process. By unlocking these secrets, we can work towards a healthier future for everyone.
Total number of samples: 1,647
- 224 (0.2%)
- 23103 (6.3%)
- 2445 (2.7%)
- 33703 (42.7%)
- 34633 (38.4%)
- 44157 (9.5%)
- NA2 (0.1%)
Dementia | ||
---|---|---|
Case | 422 | 25.6% |
Mild Cognitive Impairment (MCI) | ||
---|---|---|
Case | 1,224 | 74.3% |
NA | ||
---|---|---|
Unknown | 1 | 0.1% |